A Plus Biotechnology CoTPE:6918 -1.59%71 PEG Ratio is 0.61 as of Jul. 08, 2026, which is 10% below its 10-year median of 0.68. GuruFocus rates TPE:6918 with a GF Score™ of 71/100 and a GF Value™ of NT$87.15 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 208 Medical Devices & Instruments companies, A Plus Biotechnology Co ranks better than 84.13% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for A Plus Biotechnology Co's PEG Ratio or its related term are showing as below:
TPE:6918'
s PEG Ratio Range Over the Past 10 Years
Min: 0.6 Med: 0.68 Max: 2.55
Current: 0.61
During the past 7 years, A Plus Biotechnology Co's highest PEG Ratio was 2.55. The lowest was 0.60. And the median was 0.68.
TPE:6918's PEG Ratio is ranked better than 84.13% of 208
companies
in the Medical Devices & Instruments industry
Industry Median: 1.975
vs TPE:6918: 0.61
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
A Plus Biotechnology Co (TPE:6918) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, A Plus Biotechnology Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
A Plus Biotechnology Co PEG Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's PEG Ratio distribution charts can be found below:
* The bar in red indicates where A Plus Biotechnology Co's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
A Plus Biotechnology Co (TPE:6918) has a PEG Ratio of 0.61 as of Jul. 08, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on A Plus Biotechnology Co and its competitors. This is 10% below median its historical median of 0.68. Over the past decade, A Plus Biotechnology Co's PEG Ratio has ranged from 0.60 to 2.55. According to the industry distribution chart, A Plus Biotechnology Co ranks #33 out of 208 companies in the Medical Devices & Instruments industry, placing it in the top 15.9%.
Is A Plus Biotechnology Co's PEG Ratio too high?
A Plus Biotechnology Co's current PEG Ratio of 0.61 is 10% below median its 10-year median of 0.68. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 2.55. The Medical Devices & Instruments industry median PEG Ratio is 1.98. A Plus Biotechnology Co's value of 0.61 is 69.1% below this industry median. Based on the distribution chart, A Plus Biotechnology Co ranks #33 out of 208 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, A Plus Biotechnology Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's PEG Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, A Plus Biotechnology Co ranks #33 out of 208 companies for PEG Ratio. This places A Plus Biotechnology Co in the top 16% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.98. A Plus Biotechnology Co's value of 0.61 is 69.1% below this benchmark. Historically, A Plus Biotechnology Co's own PEG Ratio has ranged from 0.60 to 2.55 over the past decade. While the company's 10-year median is 0.68 vs. the industry median of 1.98, A Plus Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Devices & Instruments company?
The median PEG Ratio among Medical Devices & Instruments companies is 1.98, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. A Plus Biotechnology Co's current PEG Ratio of 0.61 is 69.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on A Plus Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median PEG Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. A Plus Biotechnology Co's current PEG Ratio is 0.61, which is 10% below median its own 10-year median of 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.15, compared to a current price of NT$74.30 — trading 14.7% below its estimated fair value. The current PEG Ratio is 0.61, which is 10% below median its 10-year median of 0.68 and 69.1% below the Medical Devices & Instruments industry median of 1.98. A Plus Biotechnology Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current PEG Ratio is 0.61 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?
Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued.
The current stock price of NT$74.30 is trading 14.7% below its estimated GF Value™ of NT$87.15.
GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.
Key valuation signals for TPE:6918:
PEG Ratio: 0.61 (10% below median its 10-year median of 0.68)
GF Value™: NT$87.15 vs. price of NT$74.30 (14.7% below fair value)
Industry Position: 69.1% below the Medical Devices & Instruments median (#33 of 208)
No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
71GF Score
Get the complete analysis for TPE:6918
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6918 has been successfully added to your 
